---
title: "Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Clinical trials questions"
description: "Clinical trials questions on Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Outcome measures, Study results, and Long-term data. Questions: How was the Verzenio monarchE trial designed? Who was enrolled in the Verzenio monarchE trial (Cohort 1)? What does IDFS mean in the Verzenio monarchE trial? What were the 7-year IDFS results with Verzenio in monarchE? 5 further questions follow. 9 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Clinical trials questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Verzenio](https://uspl.lilly.com/verzenio/verzenio.html#pi)

Questions that apply to every indication of Verzenio are on [Verzenio (abemaciclib), all indications](https://www.evicenter.com/medical-information/verzenio).

## Clinical trials

<a id="verzenio-monarche-design"></a>

### How was the Verzenio monarchE trial designed?

> “Graphic illustrating the design of the monarchE phase III global trial of Verzenio for the treatment of adults with node-positive, HR+, HER2– EBC at high risk of recurrence. This study included 2 Cohorts. To be enrolled in Cohort 1 (n=5,120), which is the FDA-approved population, patients had to have 1-3 positive nodes plus tumors that were either ≥5cm or histological Grade 3, or both—or patients with 4+ positive nodes. To be enrolled in Cohort 2 (n=517), patients had to have 1-3 positive nodes and Ki-67 score ≥20%.
>
> Patients in each cohort were randomized 1:1 to receive either Verzenio 150 mg twice daily plus SoC adjuvant ET (Cohort 1, n=2,555; Cohort 2, n=253) or SoC adjuvant ET alone (Cohort 1, n=2,565; Cohort 2, n=264) for 2 years. ET continued for at least 5 years if deemed medically appropriate.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=Graphic%20illustrating%20the%20design%20of,years%20if%20deemed%20medically%20appropriate.)

> “The primary endpoint was IDFS and the key secondary endpoints were DRFS and OS.<sup>3,5</sup>”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=The%20primary%20endpoint%20was%20IDFS,secondary%20endpoints%20were%20DRFS%20and)

<a id="verzenio-monarche-patients"></a>

### Who was enrolled in the Verzenio monarchE trial (Cohort 1)?

> “Of the 5120 patients randomized in cohort 1, the median age was 51 years (range, 22-89 years), 99% were women, 70% were White, 24% were Asian, 1.7% were Black or African American, 2.1% were American Indian or Alaska Native, and 0.1% were Native Hawaiian or Other Pacific Islander; 8% were Hispanic/Latino and 92% were not Hispanic/Latino and 0.2% were not reported/missing. Forty-three percent of patients were premenopausal. Most patients received prior chemotherapy (37% neoadjuvant, 59% adjuvant) and prior radiotherapy (96%). Sixty-five percent of the patients had 4 or more positive lymph nodes with 22% having ≥10 positive lymph nodes, 41% had Grade 3 tumor, and 24% had pathological tumor size ≥50 mm. The majority of patients (99%) had estrogen receptor positive disease and 87% had progesterone receptor positive disease. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Of%20the%205120%20patients%20randomized,anastrozole%20%2822%25%29%2C%20or%20exemestane%20%288%25%29.)

## Outcome measures

<a id="verzenio-idfs-definition"></a>

### What does IDFS mean in the Verzenio monarchE trial?

> “The major efficacy outcome for VERZENIO in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) was invasive disease–free survival (IDFS). IDFS was defined as the time from randomization to the first occurrence of: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, or death attributable to any cause. Overall survival (OS) was an additional outcome measure.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=The%20major%20efficacy%20outcome%20for,was%20an%20additional%20outcome%20measure.)

## Study results

<a id="verzenio-recurrence-7-year"></a>

### What were the 7-year IDFS results with Verzenio in monarchE?

> “Kaplan-Meier curve of invasive disease-free survival in Cohort 1 for the monarchE phase 3 global trial, showing a 27% reduction in risk of recurrence vs endocrine therapy (ET) alone (the hazard ratio was 0.73 [95% confidence interval was 0.65 to 0.82]) at 7 years. The number of events was 512 for Verzenio plus ET vs 678 for ET alone. At Month 24, Verzenio plus ET was 92.6% vs ET alone at 89.4%—a 2-year delta of 3.2%. At Month 36, Verzenio plus ET was 88.9% vs ET alone at 83.7%—a 3-year delta of 5.2%. At Month 48, Verzenio plus ET was 85.4% vs ET alone at 79.2%—a 4-year delta of 6.2%. At Month 60, Verzenio plus ET was 82.6% vs ET alone at 75.6%—a 5-year delta of 7.0%. At Month 72, Verzenio plus ET was 79.4% vs ET alone at 73.2%—a 6- year delta of 6.2%. At Month 84, Verzenio plus ET was 77.0% vs ET alone at 70.1%—a 7-year delta of 6.9%.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=Kaplan%2DMeier%20curve%20of%20invasive%20disease%2Dfree,70.1%25%E2%80%94a%207%2Dyear%20delta%20of%206.9%25.)

> “4- and 7-year IDFS analyses for this subpopulation were prespecified, but not powered or alpha controlled for testing statistical significance.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=4%2D%20and%207%2Dyear%20IDFS%20analyses,controlled%20for%20testing%20statistical%20significance.)

> “*High-risk was defined as HR+, HER2– EBC with either ≥4 positive nodes, OR 1-3 positive nodes and tumors that were ≥5 cm, histological Grade 3—or both.<sup>3</sup>”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=%2AHigh%2Drisk%20was%20defined%20as%20HR%2B%2C,%E2%89%A55%20cm%2C%20histological%20Grade%203%E2%80%94or)

<a id="verzenio-recurrence-4-year"></a>

### In monarchE, how many were recurrence-free at 4 years with Verzenio vs ET alone?

> “At the 4-year IDFS analysis (median follow-up of 42 months), 85.5% of patients remained recurrence free with Verzenio + ET vs 78.6% with ET alone (HR=0.65 [95% CI: 0.57-0.75]). Three hundred seventeen (317) IDFS events were observed with Verzenio plus ET vs 474 with ET alone. At the time of the 4-year analysis, OS was immature, and a total of 315 (6%) patients died across the two treatment arms.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=At%20the%204%2Dyear%20IDFS%20analysis,across%20the%20two%20treatment%20arms.)

> “Table 18: Efficacy Results in monarchE in Cohort 1
>
> Abbreviations: CI = confidence interval
>
>
> 	VERZENIO Plus
> Tamoxifen or an Aromatase Inhibitor
> N=2555	Tamoxifen or an Aromatase Inhibitor
> N=2565
> Invasive Disease–Free Survival (IDFS)
>      Number of patients with an event, n (%)	317 (12)	474 (18)
>      Hazard ratio (95% CI)	0.65 (0.57, 0.75)
> IDFS at 48 months, % (95% CI)	85.5 (83.8, 87.0)	78.6 (76.7, 80.4)”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Table%2018%3A%20Efficacy%20Results%20in,78.6%20%2876.7%2C%2080.4%29)

> “A statistically significant difference in IDFS was observed in the intent-to-treat (ITT) population which was primarily attributed to the patients treated in cohort 1.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=A%20statistically%20significant%20difference%20in,patients%20treated%20in%20cohort%201.)

> “4- and 7-year IDFS analyses for this subpopulation were prespecified, but not powered or alpha controlled for testing statistical significance.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=4%2D%20and%207%2Dyear%20IDFS%20analyses,controlled%20for%20testing%20statistical%20significance.)

Note: Table 18 columns are Verzenio plus tamoxifen or an aromatase inhibitor (N=2555) and tamoxifen or an aromatase inhibitor alone (N=2565), in that order.

<a id="verzenio-overall-survival"></a>

### What were Verzenio overall survival results vs endocrine therapy alone in monarchE?

> “Kaplan-Meier curve of overall survival in Cohort 1 for the monarchE phase 3 global trial, showing a 16% reduction in risk of death vs endocrine therapy (ET) alone (the hazard ratio was 0.84 [95% confidence interval was 0.71-0.98]) at 7 years. The number of events was 286 for Verzenio plus ET vs 344 for ET alone. At Month 60, Verzenio plus ET was 91.0% vs ET alone at 89.6%—a 5-year delta of 1.4%. At Month 72, Verzenio plus ET was 88.7% vs ET alone at 87.2%—a 6-year delta of 1.5%. At Month 84, Verzenio plus ET was 86.4% vs ET alone at 84.4%—a 7-year delta of 2.0%.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=Kaplan%2DMeier%20curve%20of%20overall%20survival,84.4%25%E2%80%94a%207%2Dyear%20delta%20of%202.0%25.)

> “At the time of analysis, a total of 630 (12%) of patients died across the two treatment arms. The percentage of deaths at the time of analysis was 11% (n=286) in the Verzenio + ET arm and 13% (n=344) in the ET-alone arm.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=At%20the%20time%20of%20analysis%2C,%28n%3D344%29%20in%20the%20ET%2Dalone%20arm.)

> “OS analysis for this subpopulation was exploratory and was not powered or alpha controlled for testing statistical significance.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=OS%20analysis%20for%20this%20subpopulation,controlled%20for%20testing%20statistical%20significance.)

> “A final OS analysis was conducted after 630 death events were observed in cohort 1. Exploratory OS results showed a HR of 0.84 (95% CI: 0.71, 0.98) for patients treated with VERZENIO plus Tamoxifen or an Aromatase Inhibitor compared with patients treated with Tamoxifen or an Aromatase Inhibitor in cohort 1.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=A%20final%20OS%20analysis%20was,Aromatase%20Inhibitor%20in%20cohort%201.)

<a id="verzenio-distant-relapse"></a>

### What were the 7-year distant relapse-free survival results with Verzenio in monarchE?

> “Kaplan-Meier curve of distant relapse-free survival in Cohort 1 for the monarchE phase 3 global trial, showing a 26.4% reduction in risk of distant relapse vs endocrine therapy (ET) alone (the hazard ratio was 0.736 [95% CI was 0.651 to 0.832]) at 7 years. The number of events was 448 for Verzenio plus ET vs 589 for ET alone. At Month 24, Verzenio plus ET was 94.0% vs ET alone at 91.1%—a 2-year delta of 2.9%. At Month 36, Verzenio plus ET was 90.5% vs ET alone at 86.0%—a 3-year delta of 4.5%. At Month 48, Verzenio plus ET was 87.7% vs ET alone at 82.3%—a 4-year delta of 5.4%. At Month 60, Verzenio plus ET was 85.0% vs ET alone at 78.7%—a 5-year delta of 6.3%. At Month 72, Verzenio plus ET was 82.0% vs ET alone at 76.7%—a 6-year delta of 5.3%. At Month 84, Verzenio plus ET was 79.5% vs ET alone at 74.0%—a 7-year delta of 5.5%.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=Kaplan%2DMeier%20curve%20of%20distant%20relapse%2Dfree,74.0%25%E2%80%94a%207%2Dyear%20delta%20of%205.5%25.)

> “A prespecified efficacy analysis was performed at a median follow-up of 76 months.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=delta%20of%205.5%25.-,A,median%20follow%2Dup%20of%2076%20months.)

> “DRFS analysis was not powered or alpha controlled for testing statistical significance.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=DRFS%20analysis%20was%20not%20powered%20or%20alpha%20controlled%20for%20testing%20statistical)

<a id="verzenio-dose-reduction-efficacy"></a>

### What did monarchE show about IDFS after Verzenio dose reductions?

> “The table shows hazard ratios for comparisons between patients who remained on a full dose of Verzenio (abemaciclib) versus those who had dose reductions.”

Source: [VERZENIO: Dosing | HCP Dosing, captured 2026-11-14](https://verzenio.lilly.com/hcp/dosing#:~:text=The%20table%20shows%20hazard%20ratios,those%20who%20had%20dose%20reductions.)

> “The primary outcome measure for monarchE is invasive disease-free survival (IDFS)”

Source: [VERZENIO: Dosing | HCP Dosing, captured 2026-11-14](https://verzenio.lilly.com/hcp/dosing#:~:text=The%20primary%20outcome%20measure%20for%20monarchE%20is%20invasive%20disease%2Dfree%20survival%20%28IDFS%29)

> “The hazard ratio for patients in cohort 1 of monarchE who received 100 mg or 50 mg Verzenio + endocrine therapy (ET) vs. 150 mg full dose was 0.90 (0.72, 1.13).”

Source: [VERZENIO: Dosing | HCP Dosing, captured 2026-11-14](https://verzenio.lilly.com/hcp/dosing#:~:text=The%20hazard%20ratio%20for%20patients,dose%20was%200.90%20%280.72%2C%201.13%29.)

> “In monarchE abemaciclib-treated patients, 1,221 patients had one or more dose reductions.”

Source: [VERZENIO: Dosing | HCP Dosing, captured 2026-11-14](https://verzenio.lilly.com/hcp/dosing#:~:text=In%20monarchE%20abemaciclib%2Dtreated%20patients%2C%201%2C221%20patients%20had%20one%20or%20more%20dose%20reductions.)

> “The presented results were based on exploratory post-hoc analyses using time-dependent Cox proportional hazard model in monarchE, MONARCH2, and MONARCH3. They were not powered or alpha controlled to test statistical significance. Notably, the analyses were conducted to assess the impact on efficacy when Verzenio dose reduction was implemented as a measure to manage toxicity, but the trials were not designed to compare different dosing strategies.<sup>1,2</sup>”

Source: [VERZENIO: Dosing | HCP Dosing, captured 2026-11-14](https://verzenio.lilly.com/hcp/dosing#:~:text=The%20presented%20results%20were%20based,designed%20to%20compare%20different%20dosing)

Note: The dosing page of the Verzenio HCP site cites Goetz et al., NPJ Breast Cancer 2024, for the monarchE dose-reduction analysis.

## Long-term data

<a id="verzenio-long-term-safety"></a>

### Did Verzenio safety change at the monarchE 5-year analysis?

> “In the monarchE safety population (N=5,591)
>
> Adverse reactions (ARs) were consistent with the known safety profile for Verzenio<sup>1</sup>
> At the 5-year analysis, safety results were consistent with prior analysis<sup>1</sup>”

Source: [VERZENIO: Adverse Reactions | HCP Safety, captured 2026-11-14](https://verzenio.lilly.com/hcp/safety-adverse-reactions#:~:text=In%20the%20monarchE%20safety%20population,results%20were%20consistent%20with%20prior)

> “The median duration of VERZENIO treatment was 24 months (range: 1-28 months).”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=The%20median%20duration%20of%20VERZENIO%20treatment%20was%2024%20months%20%28range%3A%201%2D28%20months%29.)

Note: Tables 8 and 9 of the Prescribing Information give the monarchE adverse reaction and laboratory rates.

## Related pages
- [Medical information: Verzenio (abemaciclib): HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/indication)
- [Safety](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/guidelines)
